Baxter International | BAX - Cash And Equivalent


Baxter International reported $2.15B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
AngioDynamics USD 41.64M 14.26M Sep/2025
Artivion USD 77.32M 21.55M Jun/2026
AtriCure USD 167.79M 21.62M Jun/2026
Baxter International USD 2.15B 133M Jun/2026
Becton, Dickinson and Co. USD 708M 105M Jun/2026
Boston Scientific USD 539M 914M Jun/2026
Cooper Companies USD 138.8M 13.9M Mar/2026
Dexcom USD 1.1B 13.2M Jun/2026
Edwards Lifesciences USD 2.9B 500M Jun/2026
Fresenius EUR 2.06B 752M Mar/2026
Globus Medical USD 507.74M 53.2M Jun/2026
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
ICU Medical USD 288.33M 19.63M Mar/2026
Inogen USD 106.48M 2.79M Sep/2025
Insulet USD 534.9M 54.5M Jun/2026
Integra LifeSciences USD 214.42M 22.39M Jun/2026
Intuitive Surgical USD 8.63B 646.3M Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Laboratory Of America USD 141.8M 839.3M Jun/2026
Medtronic USD 1.69B 258M Jun/2026
Merit Medical Systems USD 448.7M 39.38M Jun/2026
Quest Diagnostics USD 626M 233M Jun/2026
Stryker USD 3.39B 513M Jun/2026
Tandem Diabetes Care USD 62.82M 116.51M Jun/2026
Teleflex USD 300.16M 9.25M Jun/2026
Terumo JPY 280.49B 63.34B Mar/2026
Zimmer Biomet Holdings USD 410M 14.2M Jun/2026